- Home
- ADNT vs TNGX Comparison
ADNT vs TNGX Comparison
Compare ADNT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADNT | TNGX |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ADNT | TNGX |
|---|---|---|
| Price | $24.86 | $12.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $24.85 | $14.33 |
| AVG Volume (30 Days) | 1.0M | ★ 2.2M |
| Earning Date | 05-05-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,439,000,000.00 | $42,069,000.00 |
| Revenue This Year | $2.76 | $52.63 |
| Revenue Next Year | $2.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.56 | ★ 15.17 |
| 52 Week Low | $10.04 | $1.04 |
| 52 Week High | $27.32 | $13.48 |
Technical Indicators
Market Signals| Indicator | ADNT | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 54.30 | 55.56 |
| Support Level | $25.53 | $12.12 |
| Resistance Level | $27.32 | $13.18 |
| Average True Range (ATR) | 1.15 | 0.72 |
| MACD | -0.09 | -0.09 |
| Stochastic Oscillator | 57.66 | 43.82 |
Price Performance
Historical ComparisonAbout ADNT Adient plc
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.